相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HDAC6 as privileged target in drug discovery: A perspective
Sravani Pulya et al.
PHARMACOLOGICAL RESEARCH (2021)
The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Gianluca Mauri et al.
CANCERS (2021)
Design and Synthesis of Hsp90 Inhibitors with B-Raf and PDHK1 Multi-Target Activity
Luca Pinzi et al.
CHEMISTRYOPEN (2021)
Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole Compounds
Veronika Palusova et al.
CANCERS (2020)
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Terence C. S. Ho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Recent Update of HDAC Inhibitors in Lymphoma
I-Chung Chen et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia
Marco Spreafico et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
Alicja Puszkiel et al.
CLINICAL PHARMACOKINETICS (2019)
Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies
Xuewu Liang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAFV600E : An In Vitro
Hao Fu et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors
Aixin Geng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy
Yepeng Luan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
Rui Ma et al.
BRITISH JOURNAL OF CANCER (2018)
Zinc binding groups for histone deacetylase inhibitors
Lei Zhang et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2018)
Histone deacetylase 6 in cancer
Ting Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
New perspectives for targeting RAF kinase in human cancer
Zoi Karoulia et al.
NATURE REVIEWS CANCER (2017)
Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-RafV600E inhibitors
Xiaokai Li et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Structural insights into HDAC6 tubulin deacetylation and its selective inhibition
Yasuyuki Miyake et al.
NATURE CHEMICAL BIOLOGY (2016)
Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity
Charles H. Adelmann et al.
ONCOTARGET (2016)
Dual inhibition of BRAF and MEK in BRAF-mutated metastatic non-small cell lung cancer
Young Hak Kim
JOURNAL OF THORACIC DISEASE (2016)
Inhibition of RAF lsoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng et al.
CANCER CELL (2015)
N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors
Yingjun Li et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
AutoDock4Zn: An Improved Auto Dock Force Field for Small-Molecule Docking to Zinc Metalloproteins
Diogo Santos-Martins et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib
Huimin Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Matthew Holderfield et al.
NATURE REVIEWS CANCER (2014)
BRAF mutation in hairy cell leukemia
Ahmad Ahmadzadeh et al.
ONCOLOGY REVIEWS (2014)
Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates
Christopher J. Millard et al.
MOLECULAR CELL (2013)
Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3
F. Lai et al.
CELL DEATH & DISEASE (2013)
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors
Tara R. Rheault et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions
Mats H. M. Olsson et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2011)
Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
Kyle V. Butler et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility
Garrett M. Morris et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2009)
Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
Paul A. Marks et al.
NATURE BIOTECHNOLOGY (2007)
The Amber biomolecular simulation programs
DA Case et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2005)
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas
K Fransén et al.
CARCINOGENESIS (2004)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention
F Chang et al.
LEUKEMIA (2003)
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation
SJ Haggarty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
